Stockscreener 앱 받기
29.23
0.94%
-0.2579
전일 마감가:
$29.49
열려 있는:
$29.75
하루 거래량:
1.16M
Relative Volume:
0.57
시가총액:
$3.01B
수익:
$164.01M
순이익/손실:
$-65.04M
주가수익비율:
-42.55
EPS:
-0.687
순현금흐름:
$-383.84M
1주 성능:
-11.04%
1개월 성능:
-7.99%
6개월 성능:
+6.19%
1년 성능:
+63.30%
1일 변동 폭
$28.72
$30.00
1주일 범위
$28.64
$32.56
52주 변동 폭
$15.60
$36.44
빔 테라퓨틱스 Stock (BEAM) Company Profile
명칭
Beam Therapeutics Inc
전화
857-327-8775
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
29.25 | 3.03B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
443.52 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.26 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
896.00 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.74 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.22 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
빔 테라퓨틱스 Stock (BEAM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-10-09 | 개시 | Jefferies | Buy |
| 2025-03-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-10 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-07-23 | 개시 | H.C. Wainwright | Buy |
| 2024-01-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-10-20 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 개시 | Citigroup | Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-01-05 | 개시 | Guggenheim | Buy |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-09-24 | 재개 | Stifel | Buy |
| 2021-09-10 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Redburn | Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 개시 | Wells Fargo | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-08-05 | 개시 | William Blair | Outperform |
| 2020-03-02 | 개시 | Barclays | Overweight |
| 2020-03-02 | 개시 | JP Morgan | Overweight |
| 2020-03-02 | 개시 | Jefferies | Buy |
| 2020-03-02 | 개시 | Wedbush | Outperform |
모두보기
빔 테라퓨틱스 주식(BEAM)의 최신 뉴스
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics (Nasdaq: BEAM) shareholders approve directors, auditor and pay - Stock Titan
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History - Benzinga
Beam Therapeutics (BEAM) director receives 19,676-share option grant - Stock Titan
Beam Therapeutics (BEAM) director receives stock options grant for 19,676 shares - Stock Titan
Beam Therapeutics (BEAM) grants 19,676 stock options to director - Stock Titan
Beam Therapeutics (BEAM) director receives stock options on 19,676 shares - Stock Titan
Beam Therapeutics (BEAM) awards stock options to director Chirfi - Stock Titan
Beam Therapeutics (BEAM) awards director Graham Cooper 19,676 options - Stock Titan
BEAM Stock Price, Quote & Chart - ChartMill
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock - Investing.com
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Beam Therapeutics CEO Evans sells $739k in stock - Investing.com
BEAM Technical Analysis & Stock Price Forecast - Intellectia AI
Beam Therapeutics Stock Hits Day Low of $28.80 Amid Price Pressure - Markets Mojo
Beam Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
BEAM Technical Analysis | Trend, Signals & Chart Patterns | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Technical Reactions to BEAM Trends in Macro Strategies - Stock Traders Daily
Draft FDA guidance could be a boon for gene therapy developers - Seeking Alpha
Beam Therapeutics eyes sickle cell BLA as Alpha-1 gene-editing program advances - MSN
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - AOL.com
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - Quantisnow
Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD - Yahoo Finance
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam - Intellectia AI
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout
ADAR1 Capital Management, LLC's Beam Therapeutics Inc(BEAM) Holding History - GuruFocus
Trading the Move, Not the Narrative: (BEAM) Edition - Stock Traders Daily
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
CCORF Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $75 - Moomoo
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International ConferenceSlideshow - Seeking Alpha
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances - Barchart.com
BEAM: Lead gene editing programs advance toward approval with strong efficacy, safety, and payer value - TradingView
Beam Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock - Insider Monkey
In Vivo Gene Editing Market is expected to Hit US$ 37.75 Billion - openPR.com
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed? - Sahm
Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus - Yahoo Finance
Beam Therapeutics (BEAM) Advances Phase 1/2 Trial for AAT Deficiency - GuruFocus
Verve Therapeutics : VERV - 24/7 Wall St.
Beam Therapeutics presents AATD gene therapy trial data at ATS - Investing.com UK
Beam Therapeutics presents AATD gene therapy trial data at ATS By Investing.com - Investing.com Australia
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
One-time gene-editing AATD therapy BEAM-302 seeks accelerated FDA path - Stock Titan
빔 테라퓨틱스 (BEAM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.02%
2.34%
자본화:
|
볼륨(24시간):